Valilactone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329472

CAS#: 113276-96-3

Description: Valilactone is a fatty acid synthase inhibitor produced by a cultured strain of soil actinomycetes. Fatty acid synthase (FAS) is necessary for growth and survival of tumor cells and is a promising drug target for oncology.


Price and Availability

Size
Price

5mg
USD 450
Size
Price

10mg
USD 850
Size
Price

Valilactone, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329472
Name: Valilactone
CAS#: 113276-96-3
Chemical Formula: C22H39NO5
Exact Mass: 397.2828
Molecular Weight: 397.556
Elemental Analysis: C, 66.47; H, 9.89; N, 3.52; O, 20.12


Synonym: Valilactone; (-)-Valilactone

IUPAC/Chemical Name: 1-((2S,3R)-3-hexyl-4-oxooxetan-2-yl)heptan-2-yl formyl-L-valinate

InChi Key: WWGVIIVMPMBQFV-HNNZKPGWSA-N

InChi Code: InChI=1S/C22H39NO5/c1-5-7-9-11-13-18-19(28-21(18)25)14-17(12-10-8-6-2)27-22(26)20(16(3)4)23-15-24/h15-20H,5-14H2,1-4H3,(H,23,24)/t17?,18-,19+,20+/m1/s1

SMILES Code: CC(C)[C@@H](C(OC(C[C@@H]([C@H]1CCCCCC)OC1=O)CCCCC)=O)NC=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Richardson RD, Ma G, Oyola Y, Zancanella M, Knowles LM, Cieplak P, Romo D, Smith JW. Synthesis of novel beta-lactone inhibitors of fatty acid synthase. J Med Chem. 2008 Sep 11;51(17):5285-96. doi: 10.1021/jm800321h. PubMed PMID: 18710210; PubMed Central PMCID: PMC3172131.

2: Ma G, Zancanella M, Oyola Y, Richardson RD, Smith JW, Romo D. Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase. Org Lett. 2006 Sep 28;8(20):4497-500. PubMed PMID: 16986934.

3: Wu Y, Sun YP. An expeditious enantioselective total synthesis of valilactone. J Org Chem. 2006 Jul 21;71(15):5748-51. PubMed PMID: 16839158.

4: Yoshinari K, Aoki M, Ohtsuka T, Nakayama N, Itezono Y, Mutoh M, Watanabe J, Yokose K. Panclicins, novel pancreatic lipase inhibitors. II. Structural elucidation. J Antibiot (Tokyo). 1994 Dec;47(12):1376-84. PubMed PMID: 7844032.

5: Kitahara M, Asano M, Naganawa H, Maeda K, Hamada M, Aoyagi T, Umezawa H, Iitaka Y, Nakamura H. Valilactone, an inhibitor of esterase, produced by actinomycetes. J Antibiot (Tokyo). 1987 Nov;40(11):1647-50. PubMed PMID: 3693135.